In Q3 2025, Eventide Asset Management held 186 positions worth $4.7B. They initiated 16 new positions and exited 101. Their largest holding was GH ($207.5M).
Frequently asked questions
What stocks did Eventide Asset Management own in Q3 2025?
Eventide Asset Management held 186 biotech stocks in their 13F portfolio in Q3 2025. Their top positions include GH, MIRM, XMTR, TT, INSM. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Eventide Asset Management's portfolio worth in Q3 2025?
Eventide Asset Management's tracked biotech portfolio was worth $4.7B across 186 positions, with total assets under management of approximately $6B. Portfolio values are based on 13F filings with the SEC.
What did Eventide Asset Management buy in Q3 2025?
Eventide Asset Management initiated 16 new positions in Q3 2025, including AAVXF, SLNO, BLTE, OCUL, CAT and 11 more. They also increased 112 existing positions.
What did Eventide Asset Management sell in Q3 2025?
Eventide Asset Management fully exited 101 positions in Q3 2025, including WEAV, ZNTL, BCRX, BHVN, BPMC and 96 more. They also trimmed 51 existing positions.
Is Eventide Asset Management a biotech fund?
Values-based investment firm with significant biotech allocation. Kuruvilla—a physician, engineer, and PhD—leads a team that evaluates companies on both financial merit and alignment with ethical principles. Known for holding high-conviction biotech positions alongside broader healthcare and technology investments.
Want AI analysis, insider signals, and catalyst overlays for Eventide Asset Management?
View latest Eventide Asset Managementportfolio →